A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
The distinction between serous neoplasms of the peritoneum in women and conventional mesothelioma can be difficult. In order to determine any significant immunohistochemical differences, formalin-fixed, paraffin-embedded sections of 10 peritoneal serous tumors (PST), 10 ovarian serous tumors (OST), and 10 epithelial mesotheliomas were evaluated with a panel of 10 antibodies directed against carcinoembryonic antigen (CEA: polyclonal, monoclonal), high molecular weight keratin (34 beta E12), low molecular weight keratin (35 beta H11), Leu-M1, TAG-72 (monoclonal antibody B72.3), human milk fat globulin (HMFG-2), vimentin, placental alkaline phosphatase (PLAP), and S-100 protein. The antibodies CEA, Leu-M1, and B72.3 had the most discriminatory value in differentiating serous tumors from mesothelioma. Eighty-five percent of PSTs and OSTs (17 of 20) were positive with CEA, Leu-M1, and/or B72.3. None of the mesotheliomas stained for CEA or Leu-M1; three mesotheliomas had very focal positivity with B72.3 (1% or less). Vimentin, PLAP, HMGF-2, keratin, and S-100 had no significant discriminatory value. Epithelial mucin was present in 80% of serous tumors, while the mesotheliomas lacked epithelial mucin. Leu-M1, CEA, and/or B72.3 positivity in a peritoneal tumor supports a diagnosis of serous tumor. However, since some PST do not stain for any of the three antibodies and the focal nature of positive reactions in some cases may be difficult to interpret, exclusion of mesotheliomas is enhanced by the use of mucin stains.
Khoury
N
N
Department of Pathology, Henry Ford Hospital, Detroit, MI 48202.
Raju
U
U
Crissman
J D
JD
Zarbo
R J
RJ
Greenawald
K A
KA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase; D000906:Antibodies; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000096:biosynthesis; D003937:Diagnosis, Differential; D005260:Female; D058851:GPI-Linked Proteins; D015870:Gene Expression; D006023:Glycoproteins; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis; D007633:Keratins / Q000096:biosynthesis; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D008654:Mesothelioma / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D018396:Mucin-1; D009077:Mucins / Q000096:biosynthesis; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000473:pathology*; D010997:Pleural Neoplasms / Q000378:metabolism / Q000473:pathology; D009418:S100 Proteins / Q000096:biosynthesis; D014746:Vimentin / Q000096:biosynthesis
D000906:Antibodies; D015214:Antigens, Differentiation, Myelomonocytic; D000951:Antigens, Neoplasm; D058851:GPI-Linked Proteins; D006023:Glycoproteins; D007527:Isoenzymes; D008562:Membrane Glycoproteins; D018396:Mucin-1; D009077:Mucins; D009418:S100 Proteins; D014746:Vimentin; C047052:tumor-associated antigen 72; D007633:Keratins; D000469:Alkaline Phosphatase; C019839:alkaline phosphatase, placental